July 1, 2009Journal of Hypertension
Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor
Key result
Telmisartan provided cardiovascular protection that was noninferior to ramipril, while their combination was not superior to ramipril alone.
Why the study?
Does telmisartan alone or in combination with ramipril provide noninferior cardiovascular protection compared to ramipril in high-risk patients without heart failure?
Population
High-risk patients without congestive heart failure and/or left ventricular hypertrophy/dysfunction…
Comparison
Telmisartan alone or in combination with ramipril vs Ramipril alone
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May offer a better-tolerated ramipril alternative in high-risk patients; supports ARB-ACEI equivalence but leaves combination benefits unresolved.
Study Design
Type
RCT
Multicenter
Yes
Structured PICO
Does telmisartan alone or in combination with ramipril provide noninferior cardiovascular protection compared to ramipril in high-risk patients without heart failure?
P
Population
High-risk patients without congestive heart failure and/or left ventricular hypertrophy/dysfunction.
I
Intervention
Telmisartan alone or in combination with ramipril
C
Comparator
Ramipril alone
O
Outcome
Prevention of cardiovascular events (cardiovascular protection)
Telmisartan provides comparable cardiovascular efficacy to ramipril with fewer adverse events like cough and angioedema in high-risk patients, potentially improving compliance.
Cite This Study
Peter Sleight (2009) conducted an RCT in High cardiovascular risk. Telmisartan alone or in combination with ramipril vs. Ramipril alone was evaluated on Cardiovascular protection (cardiovascular events). Telmisartan provided cardiovascular protection that was noninferior to ramipril, while their combination was not superior to ramipril alone.